Cover Image
市場調查報告書

副神經節瘤(頸靜脈球瘤)- 開發中產品分析

Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H2 2014

出版商 Global Markets Direct 商品編碼 255967
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
副神經節瘤(頸靜脈球瘤)- 開發中產品分析 Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H2 2014
出版日期: 2014年12月31日 內容資訊: 英文 54 Pages
簡介

副神經節瘤(頸靜脈球瘤)是末稍神系統細胞發生的腫瘤,症狀有高血壓、心搏過速,頭痛,頭部充血,發汗等。治療有外科手術或化療等選擇。

本報告提供副神經節瘤(頸靜脈球瘤)的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

副神經節瘤(頸靜脈球瘤)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 臨床階段的產品

開發中的產品:各企業

治療藥的開發企業

  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Progenics Pharmaceuticals, Inc.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • dovitinib lactate
  • everolimus
  • iobenguane sulfate I 131
  • sunitinib malate
  • vandetanib

最新的開發平台資訊

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC5898IDB

Summary

Global Markets Direct's, 'Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H2 2014', provides an overview of the Paraganglioma (Glomus Jugulare Tumor)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Paraganglioma (Glomus Jugulare Tumor), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paraganglioma (Glomus Jugulare Tumor) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Paraganglioma (Glomus Jugulare Tumor)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Paraganglioma (Glomus Jugulare Tumor) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Paraganglioma (Glomus Jugulare Tumor) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Paraganglioma (Glomus Jugulare Tumor) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Paraganglioma (Glomus Jugulare Tumor)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Paraganglioma (Glomus Jugulare Tumor) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Paraganglioma (Glomus Jugulare Tumor) Overview
  • Therapeutics Development
    • Pipeline Products for Paraganglioma (Glomus Jugulare Tumor) - Overview
    • Pipeline Products for Paraganglioma (Glomus Jugulare Tumor) - Comparative Analysis
  • Paraganglioma (Glomus Jugulare Tumor) - Therapeutics under Development by Companies
  • Paraganglioma (Glomus Jugulare Tumor) - Pipeline Products Glance
    • Clinical Stage Products
  • Paraganglioma (Glomus Jugulare Tumor) - Products under Development by Companies
  • Paraganglioma (Glomus Jugulare Tumor) - Companies Involved in Therapeutics Development
    • AstraZeneca PLC
    • Novartis AG
    • Pfizer Inc.
    • Progenics Pharmaceuticals, Inc.
  • Paraganglioma (Glomus Jugulare Tumor) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • dovitinib lactate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • everolimus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • iobenguane sulfate I 131 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sunitinib malate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vandetanib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Paraganglioma (Glomus Jugulare Tumor) - Recent Pipeline Updates
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor), H2 2014
  • Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor) - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Paraganglioma (Glomus Jugulare Tumor) - Pipeline by AstraZeneca PLC, H2 2014
  • Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Novartis AG, H2 2014
  • Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Pfizer Inc., H2 2014
  • Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Route of Administration, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Paraganglioma (Glomus Jugulare Tumor) Therapeutics - Recent Pipeline Updates, H2 2014

List of Figures

  • Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor), H2 2014
  • Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor) - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Clinical Stage Development, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top